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mental cost of €496, resulting in an incremental cost-effectiveness
ratio of €5470/LYG. LYG and incremental costs were respec-
tively most sensitive to time-horizon and the effect of Hexvix on
recurrence rate (€3,251/LYG to €25,549/LYG). CONCLUSION:
Compared to standard white light cystoscopy alone, in this hypo-
thetical model adding Hexvix to this procedure appears to be
cost-effective in Belgium from the health care payer’s perspective.
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OBJECTIVES: To determine the cost-effectiveness of sunitinib
malate versus best supportive care (BSC) after failure of cytokine
immunotherapy from the perspective of the Belgian public payers
(INAMI/RIZIV). METHODS: A Markov model was constructed
to simulate disease progression after failure on ﬁrst-line cytokine
therapy. Patients entered the model receiving sunitinib plus BSC
or BSC alone. The model had 3 disease states (progression-free
survival, tumor progression and move to BSC, and death) and
used monthly cycles. Outcomes in the model were valued in
terms of progression-free life years (PFLYs) and life years (LYs)
gained. The cost-effectiveness measures were cost per PFLY and
cost per LY saved. The effectiveness parameters for sunitinib
were taken from a phase II clinical trial (RTKC-0511-014). To
estimate survival for patients receiving palliative/supportive care,
data from a SEER-Medicare analysis and a study of previously-
treated patients with mRCC who were candidates for second-line
therapy (Motzer et al., 2004) were combined. Medical costs in
2006 prices were considered from the perspective of the RIZIV/
INAMI. Resource utilization was based on expert opinion from
a modiﬁed Delphi panel consisting of seven Belgian physicians
specialized in mRCC. Utilities were derived from published lit-
erature. The model incorporates the expensive cost of the termi-
nal stage (last 4 weeks of life). Future costs were discounted at
3% and effects at 1.5% in line with the Belgian pharmacoeco-
nomic guidelines. The time horizon was lifetime (10 years).
RESULTS: Treatment with sunitinib was associated with an
average gain of 5.13 PFLYs and 1.11 LYS per patient. The
incremental cost-effectiveness ratio of sunitinib versus BSC was
€7,665 per PFLY and €35,389 per LY gained. CONCLUSION:
Given the assumptions and limitations of this model, if the value
of a life year gained for cytokine-refractory mRCC patients is at
least €35,389 sunitinib should be considered a cost-effective
therapy.
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OBJECTIVES: Primary prophylaxis with granulocyte-colony
stimulating factors, used in the ﬁrst and subsequent cycles of
chemotherapy, is recommended by the 2006 ASCO and EORTC
guidelines when the overall risk of febrile neutropenia (FN)
is 20%. We evaluated the cost-effectiveness of pegﬁlgrastim
versus ﬁlgrastim used for 11 days (as used in clinical trials) and
6 days (often used in clinical practice) in patients with aggressive
non-Hodgkin’s lymphoma (NHL) receiving CHOP-21 chemo-
therapy in Italy. METHODS: A decision-analytic model was
constructed from a health care payer’s perspective with a life-
time model horizon. Costs (2006 value) including drugs, drug
administration, FN-related hospitalisations, and subsequent
medical costs were acquired from ofﬁcial price lists or literature.
FN risk, FN case-fatality, relative dose intensity (RDI), and
impact of RDI on survival were based on data from a compre-
hensive literature review and expert panel validation. Using data
from a meta-analysis and several observational studies, we esti-
mated that the absolute risk of FN in patients receiving peg-
ﬁlgrastim decreased from 19.6% to 13.1% (6.5 percentage
points) versus 11-day ﬁlgrastim, and from 25.1% to 13.1% (12
percentage points) versus 6-day ﬁlgrastim. NHL mortality and
all-cause mortality were from literature. Sensitivity analyses were
performed on key parameters. RESULTS: Pegﬁlgrastim was cost
saving compared with 11-day ﬁlgrastim (€5053 versus €7465).
Compared with 6-day ﬁlgrastim, the incremental cost-
effectiveness ratio (ICER) was €475 per FN event avoided or €5
per 1% decrease in absolute risk of FN. Pegﬁlgrastim achieved
0.112 more discounted life-years (LY) at a minimal cost increase
of €57 (€5053 versus €4996) per person, yielding an ICER of
€513/LY gained. Results were most sensitive to the relative risk of
FN for ﬁlgrastim versus pegﬁlgrastim. CONCLUSION: In Italy,
pegﬁlgrastim was cost saving compared with 11-day ﬁlgrastim
and appeared to be cost-effective compared with ﬁlgrastim used
for 6 days per cycle of CHOP-21.
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OBJECTIVES: To study the incremental cost-effectiveness of
two 5HT3 receptor antagonists-granisetron (GR) against
ondansetron (ON)- in prevention treatment of Chemotherapy
induced nausea and vomiting (CINV). METHODS: Prospective,
multi-center, observational study on 325 naïve patients recruited
at 8 Spanish Oncology Services. Consecutive patients undergoing
1st cycle with moderate to highly emetogenic chemotherapy,
and scheduled antiemetic treatment based on GR or ON were
enrolled. After chemotherapy (day 0), daily maximum nausea
intensity and number of vomiting episodes were self-recorded
during 5 more days in a diary card. Acute CINV was deﬁned as
developed in day 0, and delayed CINV as developed or persisting
in days 1–5. Antiemetic “full” response was deﬁned as: no emesis
and no/mild nausea. Differences between GR and ON in adverse
event costs, emergency visits, or other concomitant treatments
were negligible. Only antiemetic drug direct costs were consid-
ered. Incremental Cost-Effectiveness Ratio (ICER) was computed
for 1,000 and 10,000 bootstrap samples. Mean ICER values,
bootstrap percentiles and cost-effectiveness scatterplots were
used for comparison. RESULTS: No differences were found in
acute treatment effectiveness (GR = 78.7%, ON = 79%) making
impossible to interpret ICER values. Direct mean cost was some-
what higher for GR = 36.9€ (SD = 35.3) than for ON = 34.1€
(SD = 34.2). Delayed effectiveness was higher in GR (51.8%)
than in ON (42.7%) arm, with lower mean (90%IC) costs in
GR = 19.54€ (16.57, 22.6) than in ON = 55.26€ (46.4, 64.2)
group. Bootstrap ICER mean value was 353.1 (P10 = 1120.8,
P90 = 85.7). Scatterplots in the cost-effectiveness space showed
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clear segregation. Overall treatment results were similar to
delayed treatment ones. CONCLUSION: No statistic differences
were found between treatments in acute effectiveness, and hence
cost minimization analysis was only considered. GR showed to
be more cost-effective than ON in delayed and overall emesis
treatment.
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OBJECTIVES: The purpose of this study was to evaluate the
cost-effectiveness of capecitabine (Xeloda®) for the treatment
of advanced gastric cancer (aGC). This followed EMEA
approval in March 2007 and was intended initially to inform
an appraisal by the Scottish Medicines Consortium (SMC).
METHODS: Based on clinical effectiveness evidence demon-
strating that oral capecitabine is at least as good as IV 5-FU, a
cost-minimisation analysis was performed. The replacement of
continuous infusion IV 5-FU within a standard chemotherapy
regimen including cisplatin and epirubicin (ECF) by oral
capecitabine (ECX) was assessed. This analysis investigated the
comparative drug acquisition costs of ECX versus ECF regi-
mens, plus the incremental drug administration costs associated
with providing continuous infusion IV 5-FU. The administra-
tion costs included hospital visits, transport, staff time and dis-
posables. This health care resource utilisation (HCRU) was
associated with insertion and management of central venous
access lines, drug preparation, and use of infusional drug
pumps. HCRU and unit costing evidence sources included clini-
cal trials, published literature and an expert panel of specialists
(oncology doctors, nurses and pharmacists) with experience of
aGC management. Extensive sensitivity analysis assessed areas
of potential uncertainty. The primary perspective was from the
NHS, but a societal analysis was also undertaken. RESULTS:
Additional drug acquisition costs of 634 per patient course
for capecitabine are offset by drug administration savings of
1773. The net cost saving is 1139 per patient. Sensitivity
analysis demonstrates that capecitabine remains cost saving
across a range of uncertain parameters and under a number of
realistic scenarios. Also, oral dosing confers signiﬁcant beneﬁts
to patients in terms of personal time and cost savings. CON-
CLUSION: Capecitabine is cost saving in aGC and clearly
offers good value-for-money for both the NHS and patients.
Oral administration of chemotherapy in this therapy area may
also help address capacity limitations within the cancer service.
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OBJECTIVES: Trastuzumab (T) was recently approved to treat
women with HER2+ early breast cancer (eBC) following earlier
approval for metastatic breast cancer (mBC). The objective is to
estimate the potential aggregate economic value and the incre-
mental cost-utility ratio (ICUR) over T’s life cycle in ﬁve major
European countries from 2000 to 2020. METHODS: The pro-
jected life cycle ICUR was estimated by combining the ICURs of
T in eBC and mBC in a dynamic life cycle (DLM) model. The
model also projects the economic value to society, deﬁned as
monetized cumulative net quality-adjusted life years (QALYs)
gained minus net life-cycle treatment costs. Using indication-
speciﬁc ICURs (€43,000 per QALY in mBC and €15,000 per
QALY in eBC) and epidemiological projections of disease inci-
dence in Germany, France, UK, Italy, and Spain, the projected life
cycle ICUR and cumulative economic value were estimated, dis-
counting at 3.5%. RESULTS: We project a relative increase in the
number of women with HER2+ eBC vs. HER2+ mBC—a ratio of
3.4 in 2020 up from 2.1 in 2000. Over this period, the projected
overall mean ICUR was €18,000 per QALY with a total of
800,000 discounted QALYs gained. Scenario analysis was per-
formed for alternative use rates and ICURs. When benchmarked
against potentially acceptable values per QALY of €50,000 or
€100,000, the total projected economic value of T treatment
would range from €30 to €70 billion, respectively. CONCLU-
SION: Application of a DLM estimation approach to the case of
trastuzumab demonstrates that: 1) the economic value of a
product can change due to life-cycle innovation, and 2) typical
static, indication-speciﬁc cost-effectiveness models do not
account for the interdependence of drug development and
adoption decisions over the life cycle. This raises important
policy questions about the appropriate perspective—static vs.
dynamic—and reimbursement for an innovative product whose
economic value changes over time.
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OBJECTIVES: The objective of this economic evaluation was to
estimate the cost-effectiveness of HuIFN-á as adjuvant treatment
for patients with resected cutaneous malignant melanoma in
stage IIb-III in a Swedish setting. METHODS: The economic
evaluation is based on a prospective multicentre study, in which
252 patients with totally resected cutaneous melanoma in stage
II-IV (whereof 158 high-risk patients with melanoma in stage
IIb-III) were randomised to induction treatment with dacarba-
zine (DTIC) followed by six months adjuvant treatment with
low-dose natural human interferon alpha (HuIFN-á) versus no
adjuvant treatment. A Markov model was developed to assess
the costs and clinical outcomes of DTIC/HuIFN-á compared
with no adjuvant treatment. Time-to-progression and overall
survival were based on data from the clinical study. The model
compares two groups of patients, 54 years old at base-line, and
adopts a life-long horizon. The primary clinical outcome measure
is quality-adjusted life years (QALYs) gained. Direct medical
costs were included in the analysis. An additional analysis was
performed that included costs of added years of life for the
Swedish population. Cost and outcome data were discounted
with a 3% annual rate. Sensitivity analyses were performed to
test the stability of the base case results. RESULTS: The eco-
nomic analysis showed that adjuvant treatment with HuIFN-á
for stage IIb-III melanoma patients resulted in €8200 higher costs
and 2.5 additional QALYs, leading to an incremental cost per
QALY gained of €3300 compared to no adjuvant treatment.
Including costs of added years of life increased the cost per QALY
gained to about €21,100. The results were stable in sensitivity
analyses. CONCLUSION: The economic evaluation indicates
that adjuvant treatment with HuIFN-á is cost-effective for
patients with resected cutaneous malignant melanoma in stage
IIb-III.
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